Please login to the form below
EU patent extension for Pfizer's Lipitor
The European patent for Pfizer's blockbuster cholesterol drug, Lipitor, could be extended by six months due to new paediatric data concerning the treatment
The European patent for Pfizer's blockbuster cholesterol drug, Lipitor (atorvastatin), could be extended by six months due to new paediatric data concerning the treatment.
According to the Financial Times, the extended exclusivity to May 2012 for what is currently the company's largest selling therapy could earn Pfizer $800m.
Pfizer has said it plans to launch a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.
The launch would coincide with the expiration of Lipitor's patent, when the opening of the market to generic competition would be expected to have a dramatic effect on the drug's current £11bn annual revenue.
However, Pfizer has requested a supplementary protection certificate across the EU, which would extend the company's control over supplies and pricing of Lipitor a further six months.
The certificate is part of EU regulations designed to encourage paediatric research regarding medicines.
Lipitor is usually prescribed to adults with high levels of cholesterol, however it can be given to children with the condition familial hypercholesterolaemia - a specific type of inherited high cholesterol that runs in the family.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Recognising HIV Vaccine Awareness Day
- Almirall and Evotec team up in multi-target dermatology alliance
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Scientists discover new approach to treat brain tumours
- AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
- Part 1 of the Medscape video interview series
- NHS England appoints Chris Hopson as its new chief strategy officer
- Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month
- Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children
- AbbVie submits Parkinson’s disease therapy to FDA
- When is an agency not an agency?
- Jardiance is first diabetes drug to improve CV outcomes
- Roche shares new positive Ocrevus data for MS patients
- EMA reviewing Biogen’s potential Alzheimer’s drug for use in the EU
- Almirall and Inserm Transfert to develop innovative vitiligo treatments
- How to plan, execute and refine an excellent congress experience
- GPs will play a pivotal role in integrated care
PMHub
Collected Group
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...
Latest intelligence
- When is an agency not an agency?
- The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
